Market Research Logo

Novo Nordisk A/S - Product Pipeline Review - 2016

Novo Nordisk A/S - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Novo Nordisk A/S - Product Pipeline Review - 2016’, provides an overview of the Novo Nordisk A/S’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Novo Nordisk A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Novo Nordisk A/S
The report provides overview of Novo Nordisk A/S including its business description, key facts, and locations and subsidiaries
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report assesses Novo Nordisk A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report features Novo Nordisk A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Novo Nordisk A/S’s strategic position with total access to detailed information on its product pipeline
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Novo Nordisk A/S
Identify potential new clients or partners in the target demographic
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Novo Nordisk A/S’s pipeline depth and focus of pipeline therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Table of Contents
List of Tables
List of Figures
Novo Nordisk A/S Snapshot
Novo Nordisk A/S Overview
Key Information
Key Facts
Novo Nordisk A/S - Research and Development Overview
Key Therapeutic Areas
Novo Nordisk A/S - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Novo Nordisk A/S - Pipeline Products Glance
Novo Nordisk A/S - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Novo Nordisk A/S - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Novo Nordisk A/S - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Novo Nordisk A/S - Drug Profiles
(insulin aspart + insulin degludec)
Product Description
Mechanism of Action
R&D Progress
(insulin degludec + liraglutide)
Product Description
Mechanism of Action
R&D Progress
insulin degludec
Product Description
Mechanism of Action
R&D Progress
NN-1218
Product Description
Mechanism of Action
R&D Progress
nonacog beta pegol
Product Description
Mechanism of Action
R&D Progress
NN-9535
Product Description
Mechanism of Action
R&D Progress
somapacitan
Product Description
Mechanism of Action
R&D Progress
turoctocog alfa pegol
Product Description
Mechanism of Action
R&D Progress
liraglutide (recombinant)
Product Description
Mechanism of Action
R&D Progress
liraglutide (recombinant) + NN-8828
Product Description
Mechanism of Action
R&D Progress
NN-9536
Product Description
Mechanism of Action
R&D Progress
NN-9709
Product Description
Mechanism of Action
R&D Progress
OG-217SC
Product Description
Mechanism of Action
R&D Progress
OI-338GT
Product Description
Mechanism of Action
R&D Progress
AM-833
Product Description
Mechanism of Action
R&D Progress
concizumab
Product Description
Mechanism of Action
R&D Progress
G-530L
Product Description
Mechanism of Action
R&D Progress
LAI-287
Product Description
Mechanism of Action
R&D Progress
NN-1406
Product Description
Mechanism of Action
R&D Progress
NN-9747
Product Description
Mechanism of Action
R&D Progress
NN-9748
Product Description
Mechanism of Action
R&D Progress
OI-320GT
Product Description
Mechanism of Action
R&D Progress
Insulin
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides to Agonize NMUR1 and NMUR2 for Obesity and Diabetes
Product Description
Mechanism of Action
R&D Progress
XMet-A
Product Description
Mechanism of Action
R&D Progress
Novo Nordisk A/S - Pipeline Analysis
Novo Nordisk A/S - Pipeline Products by Target
Novo Nordisk A/S - Pipeline Products by Route of Administration
Novo Nordisk A/S - Pipeline Products by Molecule Type
Novo Nordisk A/S - Pipeline Products by Mechanism of Action
Novo Nordisk A/S - Recent Pipeline Updates
Novo Nordisk A/S - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
balaglitazone
coagulation factor XIII A-subunit (recombinant)
LAI-338
liraglutide (recombinant)
NN-1952
NN-1954
NN-1955
NN-1956
NN-1998
NN-7128
NN-7129
NN-8555
NN-8828
NN-9112
NN-9161
NN-9925
NNC126-0083
OG-217GT
OG-987GT
OG-987SC
ragaglitazar
semaglutide
tifenazoxide
vatreptacog alfa (activated)
Novo Nordisk A/S - Company Statement
Novo Nordisk A/S - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Novo Nordisk A/S, Key Information
Novo Nordisk A/S, Key Facts
Novo Nordisk A/S - Pipeline by Indication, 2016
Novo Nordisk A/S - Pipeline by Stage of Development, 2016
Novo Nordisk A/S - Monotherapy Products in Pipeline, 2016
Novo Nordisk A/S - Combination Treatment Modalities in Pipeline, 2016
Novo Nordisk A/S - Partnered Products in Pipeline, 2016
Novo Nordisk A/S - Partnered Products/ Combination Treatment Modalities, 2016
Novo Nordisk A/S - Pre-Registration, 2016
Novo Nordisk A/S - Phase III, 2016
Novo Nordisk A/S - Phase II, 2016
Novo Nordisk A/S - Phase I, 2016
Novo Nordisk A/S - Preclinical, 2016
Novo Nordisk A/S - Pipeline by Target, 2016
Novo Nordisk A/S - Pipeline by Route of Administration, 2016
Novo Nordisk A/S - Pipeline by Molecule Type, 2016
Novo Nordisk A/S - Pipeline Products by Mechanism of Action, 2016
Novo Nordisk A/S - Recent Pipeline Updates, 2016
Novo Nordisk A/S - Discontinued Pipeline Products, 2016
Novo Nordisk A/S, Subsidiaries
List of Figures
Novo Nordisk A/S - Pipeline by Indication, 2016
Novo Nordisk A/S - Pipeline by Stage of Development, 2016
Novo Nordisk A/S - Monotherapy Products in Pipeline, 2016
Novo Nordisk A/S - Combination Treatment Modalities in Pipeline, 2016
Novo Nordisk A/S - Partnered Products in Pipeline, 2016
Novo Nordisk A/S - Pipeline by Top 10 Target, 2016
Novo Nordisk A/S - Pipeline by Route of Administration, 2016
Novo Nordisk A/S - Pipeline by Molecule Type, 2016
Novo Nordisk A/S - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report